CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Virus-based treatments are already approved to treat several types of cancer, and combining them with bacteria could make ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F.